Clinical Trial Update: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating eganelisib as a monotherapy and in combination with cytarabine in relapsed/refractory acute myeloid leukemia. Recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Eganelisib (eganelisib)

Snippet

Sponsor: Stelexis BioSciences | Conditions: AML, Adult, MDS | Phase 1 | Status: RECRUITING